



Media Release

Medienmitteilung

Communiqué aux Médias

Sandoz Inc.
506 Carnegie Center Drive,
Suite 400
Princeton, NJ 08540
Phone +1 609 627 8500
Fax +1 609 627 8682
www.us.sandoz.com

Sandoz launches cosyntropin liquid injection

Princeton, New Jersey; March 26, 2008 -- Sandoz today announced the introduction of cosyntropin injection in the United States. Sandoz is marketing cosyntropin injection in a ready-to-use, liquid vial of 0.25 mg/ml strength versus existing cosyntropin, which is marketed as a lyophilized powder requiring reconstitution.

Sandoz received approval for its new drug application from the US Food and Drug Administration via a 505(b)(2) pathway, for the use of cosyntropin injection as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

About Sandoz

Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of more than 950 compounds and sells its products in more than 130 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany) and Eon Labs (US) In 2007, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.2 billion

Disclaimer

The foregoing release may contain forward-looking statements regarding potential additional marketing approvals or future sales of cosyntropin injection. Any such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with cosyntropin injection to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that cosyntropin injection will receive any additional marketing approvals in any other countries, or that it will reach any particular sales levels. Management's expectations regarding cosyntropin injection could be affected by various risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sandoz is providing



this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

* * *

For further information

Sandoz US Communications:

Charles A. Bruns

609.627.8881